{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T03:32:27Z","timestamp":1767151947659,"version":"build-2238731810"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2006,6,25]],"date-time":"2006-06-25T00:00:00Z","timestamp":1151193600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2006,6,25]],"date-time":"2006-06-25T00:00:00Z","timestamp":1151193600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2006,7,1]]},"DOI":"10.1038\/nm1437","type":"journal-article","created":{"date-parts":[[2006,6,25]],"date-time":"2006-06-25T13:53:44Z","timestamp":1151243624000},"page":"852-855","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":280,"title":["Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing"],"prefix":"10.1038","volume":"12","author":[{"given":"Roman K","family":"Thomas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Nickerson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan F","family":"Simons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pasi A","family":"J\u00e4nne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Torstein","family":"Tengs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Yuza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Levi A","family":"Garraway","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"LaFramboise","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey C","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kinjal","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith","family":"O'Neill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidefumi","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neal","family":"Lindeman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwok-Kin","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana M","family":"Borras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward J","family":"Gutmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantin H","family":"Dragnev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralph","family":"DeBiasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tzu-Hsiu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen A","family":"Glatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heidi","family":"Greulich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Desany","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine K","family":"Lubeski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Brockman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"Alvarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen K","family":"Hutchison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J H","family":"Leamon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael T","family":"Ronan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory S","family":"Turenchalk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Egholm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William R","family":"Sellers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan M","family":"Rothberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Meyerson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2006,6,25]]},"reference":[{"key":"BFnm1437_CR1","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/nature03095","volume":"432","author":"C Sawyers","year":"2004","unstructured":"Sawyers, C. Targeted cancer therapy. Nature 432, 294\u2013297 (2004).","journal-title":"Nature"},{"key":"BFnm1437_CR2","doi-asserted-by":"publisher","first-page":"4342","DOI":"10.1200\/JCO.2003.04.190","volume":"21","author":"MC Heinrich","year":"2003","unstructured":"Heinrich, M.C. et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J. Clin. Oncol. 21, 4342\u20134349 (2003).","journal-title":"J. Clin. Oncol."},{"key":"BFnm1437_CR3","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","volume":"2","author":"NP Shah","year":"2002","unstructured":"Shah, N.P. et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2, 117\u2013125 (2002).","journal-title":"Cancer Cell"},{"key":"BFnm1437_CR4","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1126\/science.1099314","volume":"304","author":"JG Paez","year":"2004","unstructured":"Paez, J.G. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497\u20131500 (2004).","journal-title":"Science"},{"key":"BFnm1437_CR5","doi-asserted-by":"publisher","first-page":"13306","DOI":"10.1073\/pnas.0405220101","volume":"101","author":"W Pao","year":"2004","unstructured":"Pao, W. et al. EGF receptor gene mutations are common in lung cancers from \u201cnever smokers\u201d and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. USA 101, 13306\u201313311 (2004).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnm1437_CR6","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1056\/NEJMoa040938","volume":"350","author":"TJ Lynch","year":"2004","unstructured":"Lynch, T.J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129\u20132139 (2004).","journal-title":"N. Engl. J. Med."},{"key":"BFnm1437_CR7","doi-asserted-by":"publisher","first-page":"e73","DOI":"10.1371\/journal.pmed.0020073","volume":"2","author":"W Pao","year":"2005","unstructured":"Pao, W. et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2, e73 (2005).","journal-title":"PLoS Med."},{"key":"BFnm1437_CR8","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1056\/NEJMoa044238","volume":"352","author":"S Kobayashi","year":"2005","unstructured":"Kobayashi, S. et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 352, 786\u2013792 (2005).","journal-title":"N. Engl. J. Med."},{"key":"BFnm1437_CR9","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1126\/science.1099480","volume":"305","author":"NP Shah","year":"2004","unstructured":"Shah, N.P. et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305, 399\u2013401 (2004).","journal-title":"Science"},{"key":"BFnm1437_CR10","doi-asserted-by":"publisher","first-page":"7665","DOI":"10.1073\/pnas.0502860102","volume":"102","author":"EL Kwak","year":"2005","unstructured":"Kwak, E.L. et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc. Natl. Acad. Sci. USA 102, 7665\u20137670 (2005).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnm1437_CR11","doi-asserted-by":"publisher","first-page":"5463","DOI":"10.1073\/pnas.74.12.5463","volume":"74","author":"F Sanger","year":"1977","unstructured":"Sanger, F., Nicklen, S. & Coulson, A.R. DNA sequencing with chain-terminating inhibitors. Proc. Natl. Acad. Sci. USA 74, 5463\u20135467 (1977).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"Suppl 1","key":"BFnm1437_CR12","doi-asserted-by":"publisher","first-page":"SI5","DOI":"10.1016\/S0140-6736(99)90241-6","volume":"354","author":"GJ van Ommen","year":"1999","unstructured":"van Ommen, G.J., Bakker, E. & den Dunnen, J.T. The human genome project and the future of diagnostics, treatment, and prevention. Lancet 354 Suppl 1, SI5\u201310 (1999).","journal-title":"Lancet"},{"key":"BFnm1437_CR13","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1126\/science.281.5375.363","volume":"281","author":"M Ronaghi","year":"1998","unstructured":"Ronaghi, M., Uhlen, M. & Nyren, P. A sequencing method based on real-time pyrophosphate. Science 281, 363\u2013365 (1998).","journal-title":"Science"},{"key":"BFnm1437_CR14","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1038\/nature03959","volume":"437","author":"M Margulies","year":"2005","unstructured":"Margulies, M. et al. Genome sequencing in microfabricated high-density picolitre reactors. Nature 437, 376\u2013380 (2005).","journal-title":"Nature"},{"key":"BFnm1437_CR15","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1158\/1078-0432.CCR-05-2047","volume":"12","author":"PA Janne","year":"2006","unstructured":"Janne, P.A. et al. A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening. Clin. Cancer Res. 12, 751\u2013758 (2006).","journal-title":"Clin. Cancer Res."},{"key":"BFnm1437_CR16","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1056\/NEJMoa050736","volume":"353","author":"MS Tsao","year":"2005","unstructured":"Tsao, M.S. et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N. Engl. J. Med. 353, 133\u2013144 (2005).","journal-title":"N. Engl. J. Med."},{"key":"BFnm1437_CR17","doi-asserted-by":"publisher","first-page":"8081","DOI":"10.1200\/JCO.2005.02.7078","volume":"23","author":"DW Bell","year":"2005","unstructured":"Bell, D.W. et al. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL\/INTACT gefitinib trials. J. Clin. Oncol. 23, 8081\u20138092 (2005).","journal-title":"J. Clin. Oncol."},{"key":"BFnm1437_CR18","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1093\/annonc\/mdi221","volume":"16","author":"H Cortes-Funes","year":"2005","unstructured":"Cortes-Funes, H. et al. Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients. Ann. Oncol. 16, 1081\u20131086 (2005).","journal-title":"Ann. Oncol."},{"key":"BFnm1437_CR19","doi-asserted-by":"publisher","first-page":"e313","DOI":"10.1371\/journal.pmed.0020313","volume":"2","author":"H Greulich","year":"2005","unstructured":"Greulich, H. et al. Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med. 2, e313 (2005).","journal-title":"PLoS Med."}],"updated-by":[{"DOI":"10.1038\/nm1006-1220a","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2006,10,1]],"date-time":"2006-10-01T00:00:00Z","timestamp":1159660800000}}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nm1437.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nm1437","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nm1437.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T18:27:20Z","timestamp":1684434440000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nm1437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6,25]]},"references-count":19,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2006,7,1]]}},"alternative-id":["BFnm1437"],"URL":"https:\/\/doi.org\/10.1038\/nm1437","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,6,25]]},"assertion":[{"value":"29 November 2005","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2006","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2006","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2006","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Erratum","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In the version of this article initially published, it should have been acknowledged that Jan F. Simons, in addition to Roman K. Thomas and Elizabeth Nickerson, contributed equally to this work. The error has been corrected in the HTML and PDF versions of the article.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Matthew Meyerson and William R. Sellers have received funding from and served as consultants for Novartis, where Dr. Sellers is now employed. Matthew Meyerson has received research funding from Genentech. Jan F. Simons, Brian Desany, Christine K. Lubeski, Stephen K. Hutchinson, J.H. Leamon, Michael T. Ronan, Gregory S. Turenchalk, Michael Egholm and Jonathan M. Rothberg are employees of 454 Life Sciences. Elisabeth Nickerson was an employee of 454 Life Sciences at the time the research was conducted; she is now an employee of Helicos BioSciences. Matthew Meyerson, Pasi A. J\u00e4nne and William R. Sellers are inventors on a patent application for EGFR mutation detection as a diagnostic tool in cancer.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}